Evidence map›Paper›PMID 40366077›Full record

ArticleThe Journal of dermatology2025

Is One Year Enough? Extended Adjuvant Dabrafenib Plus Trametinib for Chinese Patients With Resected Stage III Melanoma.

Dong-Dong Jia, Yu Xu, Zhi-Wu Ren, Lin-Qing Li, Lei Zhang, Yang Li, Li-Shu Lou, Wei-Tao Yao, Zhe Liu, Xian-An Li and 3 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dong-Dong JiaDepartment of Bone and Soft-Tissue Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, Hangzhou, China.ORCID https://orcid.org/0000-0002-6804-4988
Yu XuDepartment of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China.
Zhi-Wu RenDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Lin-Qing LiDepartment of Bone and Soft-Tissue Surgery, Hunan Cancer Hospital, Changsha, Hunan, China.
Lei ZhangBone and Soft Tissue Oncology Department, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China.
Yang LiDepartment of Bone and Soft Tissue, Henan Cancer Hospital, Zhengzhou, Henan, China.
Li-Shu LouZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, Hangzhou, China.
Wei-Tao YaoDepartment of Bone and Soft Tissue, Henan Cancer Hospital, Zhengzhou, Henan, China.ORCID https://orcid.org/0000-0002-2963-8775
Zhe LiuBone and Soft Tissue Oncology Department, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China.
Xian-An LiDepartment of Bone and Soft-Tissue Surgery, Hunan Cancer Hospital, Changsha, Hunan, China.
Ji-Long YangDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.ORCID https://orcid.org/0000-0001-5162-3740
Yong ChenDepartment of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-7188-4566
Tao LiDepartment of Bone and Soft-Tissue Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, Hangzhou, China.ORCID https://orcid.org/0000-0002-5924-0522

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPathogenic BRAF mutations drive constitutive MAPK pathway activation in melanoma, and targeted therapies with dabrafenib plus trametinib have improved outcomes in the adjuvant setting. However, the optimal duration of adjuvant therapy remains unclear. This retrospective study examined whether extending dabrafenib plus trametinib beyond 1 year offers additional clinical benefit in Chinese patients with resected Stage III melanoma.

methodsMedical records from six centers were reviewed for adults with BRAF V600E/K-positive, completely resected Stage III melanoma who received at least 12 months of adjuvant dabrafenib plus trametinib. Patients were divided into a 1-year therapy group and a more-than-1-year therapy group. Relapse-free survival (RFS) was the primary end point; adverse events were also assessed.

resultsOf the 122 patients included, 77 received more than 1 year of adjuvant therapy. The more-than-1-year group experienced significantly better RFS (log-rank p = 0.04), and longer therapy independently reduced recurrence risk in multivariate analysis (HR, 2.42; p = 0.035). Adverse event profiles did not differ between groups, and toxicity-related treatment modifications occurred primarily within the first year.

conclusionsExtending dabrafenib plus trametinib beyond 1 year may provide improved RFS without increasing toxicity. Further prospective trials are warranted to confirm the impact on overall survival and identify optimal patient subsets for prolonged therapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsMelanomaNeoplasm Recurrence, LocalSkin NeoplasmsAdultAgedAged, 80 and overChemotherapy, AdjuvantChinaDisease-Free SurvivalEast Asian PeopleFemaleHumansImidazolesMaleMiddle AgedBRAF protein, humandabrafenibImidazolesOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinibchinese patientsdabrafenib plus trametinibextended adjuvant therapyrelapse‐free survivalstage III melanoma

Identifiers

PMID40366077
PMCPMC12231920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.